stockrow
Friday 6 November 2026
Export PACB’s income statement to Excel — free account
Pacific Biosciences of California, Inc.
PACB Healthcare Medical Devices
Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024.
- Revenue
- +5.52%
- EPS
- +7.69%
- Free cash flow
- −102.0%
- Total debt
- −0.29%
Quarter to September 2026, against a year earlier
2.29
0.14
−5.76%
Follow PACB
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.17 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 2 | 3 | 2 | 3 | 6 | 4 | 4 | 3 | 2 |
P/S ratio |
3.51 | 3.26 | 12.13 | 13.90 | 32.00 | 54.31 | 8.63 | 12.71 | 3.15 | 4.28 |
Altman Z-Score |
(6.04) | (2.70) | (0.12) | (0.40) | 1.55 | 29.53 | (6.40) | 1.84 | (6.46) | (4.57) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 232.07 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(13.42) | (5.15) | (1.59) | (1.32) | 1.36 | (0.35) | (26.02) | (16.62) | (19.21) | (16.84) |
Beneish M-Score |
(5.14) | (3.16) | (1.48) | (2.83) | (1.00) | (2.35) | 0.72 | (3.79) | (3.18) | (1.38) |
P/Operating CF |
(29.42) | (16.39) | (42.26) | (29.44) | (131.72) | (300.42) | (43.12) | (52.66) | (14.60) | (30.13) |
P/B ratio |
104.86 | 0.99 | 3.47 | 3.17 | 5.28 | 12.77 | 14.28 | 8.76 | 3.42 | 4.59 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.77 | 14.28 | 8.76 | 3.42 | 4.59 |
EV/Sales |
5.79 | 4.93 | 13.43 | 14.86 | 30.86 | 50.74 | 8.54 | 11.60 | 2.63 | 3.67 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(8.33) | (3.68) | (10.39) | (7.25) | (36.23) | 205.27 | (9.92) | (13.73) | (3.64) | (4.90) |
EV/FCF |
(7.79) | (3.58) | (10.05) | (6.81) | (34.39) | 216.82 | (9.57) | (13.36) | (3.15) | (4.37) |
Quick Ratio |
4.32 | 6.31 | 7.03 | 3.01 | 14.91 | 8.74 | 1.32 | 4.13 | 2.66 | 2.47 |
Current Ratio |
5.15 | 7.48 | 7.81 | 3.24 | 15.36 | 9.24 | 1.65 | 4.90 | 3.55 | 3.23 |
Net Debt/EBITDA |
(2.33) | (1.03) | (0.81) | (0.43) | 0.76 | 2.96 | 0.08 | 0.94 | 0.61 | 0.84 |
Debt/Assets |
82.31% | 51.37% | 51.10% | 50.74% | 44.65% | 9.18% | 28.38% | 8.61% | 9.46% | 11.68% |
Debt/Equity |
120.65 | 1.28 | 1.27 | 1.59 | 1.13 | 0.11 | 0.76 | 0.13 | 0.16 | 0.19 |
Asset Turnover |
0.16 | 0.10 | 0.11 | 0.07 | 0.11 | 0.28 | 0.57 | 0.50 | 0.66 | 0.67 |
Operating CF/Net income |
0.20 | 0.67 | 0.84 | 0.84 | 0.61 | 0.66 | 0.93 | 0.65 | 0.73 | 0.91 |
Capex/Depreciation |
(0.02) | (0.03) | (0.65) | (0.99) | (0.38) | (0.11) | (0.28) | (0.25) | (1.08) | (1.63) |
Interest Coverage |
(79.65) | (35.36) | (23.32) | (20.91) | (16.79) | (390.96) | (38.51) | (41.68) | (30.74) | (22.03) |
| (213.45%) | (51.30%) | (48.53%) | (46.42%) | (32.18%) | 15.06% | (99.58%) | (102.48%) | (107.97%) | (94.02%) | |
| (53.45%) | (20.61%) | (17.46%) | (16.65%) | (14.97%) | 10.46% | (52.87%) | (65.25%) | (65.39%) | (55.30%) | |
ROIC |
(93.25%) | (38.83%) | (21.73%) | (27.95%) | (20.48%) | (121.17%) | (132.25%) | (239.39%) | (152.21%) | (154.63%) |
Return on Tangible Assets |
(167.41%) | (67.38%) | (44.88%) | (49.86%) | (17.07%) | 8.60% | (135.78%) | (73.87%) | (83.13%) | (82.83%) |
Average Days of Receivables |
80.86 | 65.23 | 66.65 | 53.44 | 67.79 | 77.90 | 61.31 | 39.90 | 52.46 | 45.95 |
Research and Development Expense of Revenue |
60.81% | 87.60% | 93.34% | 150.42% | 86.50% | 81.32% | 65.61% | 79.61% | 69.89% | 74.54% |
Selling, General and Administrative Expense of Revenue |
88.43% | 113.64% | 84.69% | 125.37% | 95.10% | 92.28% | 83.06% | 80.75% | 63.25% | 52.68% |
Intangible Assets out of Total Assets |
0.42 | 0.56 | 0.53 | 0.46 | 0.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
26.04% | 46.12% | 35.97% | 61.27% | 56.21% | 22.22% | 18.04% | 29.45% | 21.77% | 21.56% |
Graham Net Nets |
(0.72) | (0.51) | (0.12) | (0.20) | (0.03) | 0.06 | (0.02) | 0.08 | 0.15 | 0.14 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.34 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(98.40%) | (62.30%) | (12.62%) | (17.63%) | (4.35%) | 0.46% | (10.70%) | (10.41%) | (31.90%) | (19.27%) |
Free Cash Flow Yield |
(21.20%) | (42.25%) | (11.02%) | (15.70%) | (2.80%) | 0.43% | (10.35%) | (6.83%) | (26.42%) | (19.59%) |
Revenue per Share |
0.53 | 0.56 | 0.79 | 0.57 | 0.64 | 0.48 | 0.60 | 0.58 | 0.88 | 1.02 |
Operating CF per Share |
(0.37) | (0.75) | (1.02) | (1.17) | (0.54) | 0.12 | (0.51) | (0.49) | (0.64) | (0.76) |
Capex per Share |
(0.03) | (0.02) | (0.03) | (0.08) | (0.03) | (0.01) | (0.02) | (0.01) | (0.10) | (0.09) |
Free Cash Flow per Share |
(0.40) | (0.77) | (1.06) | (1.25) | (0.57) | 0.11 | (0.53) | (0.51) | (0.74) | (0.85) |
Cash per Share |
0.93 | 1.42 | 2.49 | 3.44 | 5.12 | 1.94 | 0.32 | 0.76 | 0.59 | 0.81 |
Shareholders Equity per Share |
0.02 | 1.85 | 2.77 | 2.51 | 3.87 | 2.03 | 0.36 | 0.84 | 0.81 | 0.95 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.02 | 1.85 | 2.77 | 2.51 | 3.87 | 2.03 | 0.36 | 0.84 | 0.81 | 0.95 |
Free Cash Flow |
(118.92) | (212.25) | (268.02) | (280.14) | (117.11) | 18.46 | (81.15) | (68.28) | (77.91) | (76.13) |
Working Capital |
302.22 | 429.38 | 647.02 | 588.74 | 1,029.43 | 317.09 | 31.89 | 104.78 | 72.98 | 75.24 |
Capital Expenditures |
(7.71) | (6.19) | (8.84) | (16.93) | (5.93) | (1.04) | (2.84) | (1.85) | (10.39) | (8.20) |
Net Current Asset Value |
(403.68) | (258.17) | (302.66) | (352.11) | (114.85) | 277.10 | (12.02) | 75.45 | 43.64 | 55.80 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.05 | 0.04 | 0.04 | 0.13 | 0.05 | 0.01 | 0.03 | 0.02 | 0.11 | 0.09 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
16.44 | 7.37 | 0.38 | 0.41 | 0.48 | 0.37 | 0.34 | 0.22 | 0.25 | 0.35 |
Cash ROIC |
(12.78%) | (13.74%) | (12.04%) | (12.55%) | (4.29%) | 2.66% | (55.46%) | (29.55%) | (47.91%) | (44.07%) |
Accounts Receivable Turnover |
5.08 | 4.80 | 7.24 | 5.96 | 6.35 | 4.92 | 7.62 | 7.14 | 7.52 | 10.89 |
Accounts Payable Turnover |
6.11 | 7.38 | 10.91 | 6.88 | 9.83 | 7.76 | 7.46 | 6.76 | 6.74 | 7.10 |
Inventory Turnover |
2.11 | 2.02 | 2.76 | 2.11 | 3.69 | 3.36 | 3.61 | 2.61 | 3.04 | 3.50 |
Average Days of Payables |
66.37 | 51.87 | 37.21 | 55.38 | 56.04 | 28.20 | 54.24 | 45.93 | 56.44 | 65.54 |
Days of Inventory on Hand |
157.49 | 183.72 | 140.02 | 231.98 | 125.31 | 112.12 | 86.28 | 121.90 | 143.15 | 122.58 |
Average Receivables |
31.49 | 32.07 | 27.70 | 21.51 | 20.54 | 16.05 | 11.93 | 11.01 | 12.43 | 8.33 |
Average Payables |
18.68 | 15.83 | 13.55 | 11.52 | 7.29 | 5.97 | 7.55 | 7.91 | 8.73 | 6.55 |
Average Inventory |
54.02 | 57.72 | 53.53 | 37.49 | 19.41 | 13.77 | 15.60 | 20.47 | 19.35 | 13.29 |
Average Assets |
1,022.27 | 1,503.23 | 1,756.55 | 1,887.03 | 1,210.48 | 280.98 | 159.13 | 157.18 | 140.98 | 134.50 |
Average Common Equity |
255.97 | 603.95 | 632.10 | 676.95 | 563.24 | 195.20 | 84.49 | 100.08 | 85.39 | 79.10 |
Columns are period end dates · fundamentals updated 5 Nov 2026